Whitepaper: The Growing Value of RWE

The Growing Value of RWE

Harnessing new possibilities for more agile clinical development in the wake of COVID-19

The effects of COVID-19 have been acute for individuals, communities, and systems around the world, with continuing consequences. At the outset of the pandemic, the potential disruption to planned and ongoing clinical trials was especially concerning; drug development, filings and launches would be affected for years, if not decades.

This paper considers the specific role real world methodologies can play, both in addressing immediate pandemic issues and in supporting a new, more agile and patient-centric normal for clinical development.

DOWNLOAD WHITEPAPER

Complete the form below to talk with an expert:

First Name*

Last Name*

Email Address*

Title*

Company*

Country*

Please provide us with more detail of your need.*

Opt In

By selecting this box, I consent to receiving marketing communications and information about IQVIA's offering by email.

DO NOT SELL MY PERSONAL INFORMATION